|
Important: Protocol superseded July 2009 - see new version here at www.edren.co.uk.
That website is in development - you can ignore the 'This website is not ready' signs ONLY for the Transplant protocols. Others are not updated or fully transferred. |
This page describes the Edinburgh regimen for the use of the immunosuppressant sirolimus.
As an adjunct or substitute to a calcineurin phosphatase inhibitor for immunosuppression in patients in whom ciclosporin/tacrolimus have been implicated in allograft pathology.
Hypersensitivity to Sirolimus and its derivatives
Pregnancy and breast feeding
| 1mg and 2mg tablets. Doses should be given on an empty stomach. | |||||||
|
Target range 5-15ng/ml depending on whether it is an adjunct to or substitute for a CNI.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compounds which modulate CYP3A4 activity may effect Sirolimus levels. Drugs and substances which may increase sirolimus levels include:
Drugs which may decrease Sirolimus levels:
Transplant protocols developed on the Edinburgh Transplant Unit. This page first published March 2002 by Amit Adlakha, updated November 2006 and last modified
NOTE that the accuracy of any statements in this information CANNOT be guaranteed. It is published in the belief that it is correct, and we endeavour to keep it so - but we do make mistakes. Furthermore, over some subjects there are differing opinions, or differing degrees of certainty. We have usually not attempted to discuss these here because the aim has been to provide an immediate and brief guide. In all areas, prior medical knowledge is assumed. The EdRenHANDBOOK is not suitable for use by those without such a background. Contact us by email or at the address given at the foot of the contents page with any comments or corrections.